

The claims defining the invention are as follows:

1. A compound of Formula (I) or (Ia)



(I),



(Ia),


or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein:

each A is -O-;


each R is -X-Z;

X is $-(CR^7R^{7a})_m-$;

Z has Formula (II) or (IIa):



(II),



(IIa);

wherein each B is a bond or $-(CR^7R^{7a})_m-$;

each W is N;

each Y is $-(CR^7R^{7a})_m-$ or -O-;

each R^1 is aryl;

each R^2 is H, alkyl, alkenyl or alkynyl;

each R^3 is aryl or heteroaryl;

each R^4 is H, or C_{1-4} alkyl;

each R^{7a} and R^7 is independently H, F, Cl, Br, alkyl, haloalkyl, $-(CH_2)_m$-OH or $-(CH_2)_m$-C(=O)O-R^8;

each R^8 and R^{8a} is independently H, alkyl, haloalkyl, aminoalkyl, Boc-NH-alkyl, alkoxy, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-$(CH_2)_m$-H or $-(CH_2)_m$-OC(=O)-$(CH_2)_m$-H;

Boc is *tert*-butyloxycarbonyl;

each R^9 is independently $-(CR^7R^{7a})_t$-OH, $-(CR^7R^{7a})_m$-C(=O)O-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-OC(=O)O-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-OC(=O)-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-C(=O)O-R^8, $-(CR^7R^{7a})_t$-OC(=O)-R^8, or $-(CR^7R^{7a})_m$-C(=O)N$(R^8)_2$, with the proviso that when R^9 is $-(CR^7R^{7a})_t$-OH, R^3 is aryl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl;


each n is independently 1, 2 or 3;


each t is independently 1, 2, 3 or 4;

each m is independently 0, 1, 2, 3 or 4; and

optionally each of aryl, heteroaryl, alkyl, haloalkyl, alkenyl, alkynyl, aminoalkyl, alkoxy, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl and triazinyl described above, is independently substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, Br, I, alkyl, alkoxy, cyano, hydroxy, nitro, alkylamino, amino, trifluoromethyl, trifluoromethoxy, $-(CR^7R^{7a})_m$-C(=O)O-R^{8a}, haloalkyl-substituted aryl, halogen-substituted aryl, $-(CR^7R^{7a})_m$-C(=O)N$(R^{8a})_2$ or trifluoromethylsulfonyl.

2. The compound according to claim 1, wherein Z has Formula (III) or (IIIa):



(III),


(IIIa);

wherein each B is a bond or $-(CR^7R^{7a})_m$-;

each Y is $-(CR^7R^{7a})_m$- or -O-;

each R^{7a} and R^7 is independently H, F, Cl, Br, C_{1-4} alkyl, $-(CH_2)_m$-OH, C_{1-4} haloalkyl or $-(CH_2)_m$-C(=O)O-R^8;

each R^8 is independently H, C_{1-6} alkyl, C_{1-4} haloalkyl, amino-C_{1-4}-alkyl, Boc-NH-C_{1-4}-alkyl, C_{1-4} alkoxy, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-$(CH_2)_m$-H or $-(CH_2)_m$-OC(=O)-$(CH_2)_m$-H;


each R^9 is independently $-(CR^7R^{7a})_t$-OH, $-(CR^7R^{7a})_m$-C(=O)O-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-OC(=O)O-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-OC(=O)-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-C(=O)O-R^8, $-(CR^7R^{7a})_t$-OC(=O)-R^8or $-(CR^7R^{7a})_m$-C(=O)N$(R^8)_2$, with the proviso that when R^9 is $-(CR^7R^{7a})_t$-OH, R^3 is C_{6-10} aryl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl;

each n is independently 1 or 2;

each t is independently 1, 2, 3 or 4; and

each m is independently 0, 1, 2, 3 or 4.

3. The compound according to claim 2, wherein Z is



wherein each R^7 and R^{7a} is independently H, methyl, ethyl, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-R^8 or propyl;

each R^8 is independently H, methyl, ethyl, propyl, isopropyl, butyl, 1-methylpropyl, 2-methylpropyl, aminomethyl, 1-amino-2-methylpropyl, 1-aminoethyl, 2-aminoethyl, 1-aminobutyl, 1-aminopropyl, 2-aminopropyl, Boc-NH-methyl, 1-Boc-NH-2-methylpropyl, 1-Boc-NH-ethyl, 2-Boc-NH-ethyl, 1-Boc-NH-butyl, 1-Boc-NH-propyl, 2-Boc-NH-propyl, methoxy, ethoxy, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-$(CH_2)_m$-H, $-(CH_2)_m$-OC(=O)-$(CH_2)_m$-H or *tert*-butyl; and

each R^9 is independently $-(CR^7R^{7a})_t$-OH, $-(CR^7R^{7a})_m$-C(=O)O-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-OC(=O)O-R^8, $-(CR^7R^{7a})_m$-C(=O)O-$(CR^7R^{7a})_m$-OC(=O)-R^8, $-(CR^7R^{7a})_t$-OC(=O)-R^8 or $-(CR^7R^{7a})_m$-C(=O)N$(R^8)_2$, with the proviso that when R^9 is


$-(CR^7R^{7a})_t$-OH, R^3 is phenyl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl.

4. The compound according to claim 1, wherein R^3 is C_{6-10} aryl or 5-6 membered heteroaryl, and optionally each of the heteroaryl and aryl is independently substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, methylamino, ethylamino, cyano, hydroxy, nitro, amino, trifluoromethyl, trifluoromethoxy, $-(CR^7R^{7a})_m$-C(=O)O-R^{8a}, $-(CR^7R^{7a})_m$-C(=O)N$(R^{8a})_2$ or trifluoromethylsulfonyl;

each R^{7a} and R^7 is independently H, F, Cl, Br, C_{1-4} alkyl, C_{1-4} haloalkyl, $-(CH_2)_m$-OH or $-(CH_2)_m$-C(=O)O-R^8; and

each R^{8a} and R^8 is independently H, C_{1-4} alkyl, C_{1-4} haloalkyl, amino-C_{1-4}-alkyl, Boc-NH-C_{1-4}-alkyl, C_{1-4} alkoxy, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-$(CH_2)_m$-H or $-(CH_2)_m$-OC(=O)-$(CH_2)_m$-H.

5. The compound according to claim 4, wherein R^3 has one of the following formulae:



wherein each X^1 is independently O, S, NR^{11} or $CR^{12}R^{12a}$;

each X^2, X^3, X^4, X^5 and X^6 is independently N or CR^{12}; wherein at most three or four of the X^2, X^3, X^4, X^5 and X^6 are N;

each R^{10} is independently H, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, methylamino, ethylamino, cyano, hydroxy, nitro, amino, trifluoromethyl, trifluoromethoxy, $-(CR^7R^{7a})_m$-C(=O)O-R^{8a}, $-(CR^7R^{7a})_m$-C(=O)N$(R^{8a})_2$ or trifluoromethylsulfonyl;

each R^{11} is independently H, methyl, ethyl, propyl, isopropyl, butyl, trifluoromethyl, $-(CR^7R^{7a})_m$-C(=O)N$(R^{8a})_2$ or $-(CR^7R^{7a})_m$-C(=O)O-R^{8a};

each R^{12} and R^{12a} is independently H, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, methylamino, ethylamino, cyano, hydroxy, nitro, amino, trifluoromethyl, trifluoromethoxy, $-(CR^7R^{7a})_m$-C(=O)O-R^{8a}, $-(CR^7R^{7a})_m$-C(=O)N$(R^{8a})_2$ or trifluoromethylsulfonyl;


each R^{7a} and R^7 is independently H, F, Cl, Br, C_{1-4} alkyl, $-(CH_2)_m$-OH, C_{1-4} haloalkyl or $-(CH_2)_m$-C(=O)O-R^8;

each R^{8a} and R^8 is independently H, C_{1-4} alkyl, C_{1-4} haloalkyl, amino-C_{1-4}-alkyl, Boc-NH-C_{1-4}-alkyl, C_{1-4} alkoxy, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-$(CH_2)_m$-H or $-(CH_2)_m$-OC(=O)-$(CH_2)_m$-H;

each m is independently 0, 1, 2, 3 or 4; and

each p is independently 0, 1, 2 or 3.

6. The compound according to claim 5, wherein R^3 has one of the following formulae:



wherein each R^{10} is independently H, F, Cl, methyl, ethyl, cyano, hydroxy, nitro, amino, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy, $-(CR^7R^{7a})_m$-C(=O)O-R^{8a}, $-(CR^7R^{7a})_m$-C(=O)N$(R^{8a})_2$ or trifluoromethylsulfonyl;

each R^{11} is independently H, methyl, ethyl, propyl, isopropyl, butyl, trifluoromethyl or $-(CR^7R^{7a})_m$-C(=O)O-R^{8a};

each R^{7a} and R^7 is independently H, methyl, ethyl, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-R^8 or propyl;

each R^8 and R^{8a} is independently H, methyl, ethyl, propyl, isopropyl, butyl, 2-methylpropyl, 1-methylpropyl, aminomethyl, 1-amino-2-methylpropyl, 1-aminoethyl, 2-aminoethyl, 1-aminobutyl, 1-aminopropyl, 2-aminopropyl, Boc-NH-methyl, 1-Boc-NH-2-methylpropyl, 1-Boc-NH-ethyl, 2-Boc-NH-ethyl, 1-Boc-NH-butyl, 1-Boc-NH-propyl, 2-Boc-NH-propyl, methoxy, ethoxy, $-(CH_2)_m$-OH, $-(CH_2)_m$-C(=O)O-$(CH_2)_m$-H, $-(CH_2)_m$-OC(=O)-$(CH_2)_m$-H or *tert*-butyl; and


each p is independently 0, 1, 2 or 3.


7. The compound according to claim 1, wherein R^1 is C_{6-10} aryl, and the aryl is independently substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, Br, cyano, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, nitro, 4-(trifluoromethyl)phenyl, 3,5-*bis*(trifluoromethyl)phenyl or trifluoromethyl; and

R^2 is H, or C_{1-4} alkyl.


8. The compound according to claim 7, wherein R^1 is phenyl or a phenyl substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, Br, nitro, 4-(trifluoromethyl)phenyl, 3,5-*bis*(trifluoromethyl)phenyl or trifluoromethyl.


9. The compound according to claim 1 having Formula (IV) or (IVa),


(IV),


(IVa),

or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein Z has Formula (II) or (IIa):


(II),


(IIa);

wherein each B is a bond or $-(CR^7R^{7a})_m-$;

each W is N;

each Y is $-(CR^7R^{7a})_m-$ or -O-;

each R^2 is H, or C_{1-4} alkyl;

each R^3 is C_{6-10} aryl or 5-6 membered heteroaryl, and optionally each of the heteroaryl and aryl is independently substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, methyl, ethyl, propyl, cyano, trifluoromethyl, methoxy, $-(CR^7R^{7a})_m-C(=O)N(R^{8a})_2$ or $-(CR^7R^{7a})_m-C(=O)O-R^{8a}$;

each R^{7a} and R^7 is independently H, F, $-(CH_2)_m-OH$, $-(CH_2)_m-C(=O)O-R^8$ or C_{1-4} alkyl;

each R^8 and R^{8a} is independently H, amino-C_{1-4}-alkyl, Boc-NH-C_{1-4}-alkyl, C_{1-4} alkoxy, $-(CH_2)_m-OH$, $-(CH_2)_m-C(=O)O-(CH_2)_m-H$, $-(CH_2)_m-OC(=O)-(CH_2)_m-H$ or C_{1-6} alkyl;

each R^9 is independently $-(CR^7R^{7a})_t-OH$, $-(CR^7R^{7a})_m-C(=O)O-(CR^7R^{7a})_m-OC(=O)O-R^8$, $-(CR^7R^{7a})_m-C(=O)O-R^8$, $-(CR^7R^{7a})_m-C(=O)O-(CR^7R^{7a})_m-OC(=O)-R^8$, $-(CR^7R^{7a})_t-OC(=O)-R^8$ or $-(CR^7R^{7a})_m-C(=O)N(R^8)_2$, with the proviso that when R^9 is $-(CR^7R^{7a})_t-OH$, R^3 is C_{6-10} aryl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl;


each R^{13} is independently H, F, Cl, Br, cyano, nitro, 4-(trifluoromethyl)phenyl, 3,5-*bis*(trifluoromethyl)phenyl or trifluoromethyl;


each n is independently 1 or 2;

each t is independently 1, 2, 3 or 4; and

each m is independently 0, 1, 2, 3 or 4.

10. The compound according to claim 9, wherein Z has Formula (II) or (IIa):



(II),


(IIa);

wherein each B is a bond or $-(CR^7R^{7a})_m-$;

each W is N;

each Y is $-(CR^7R^{7a})_m-$ or -O-;

each R^{7a} and R^7 is independently H, methyl, $-(CH_2)_m-OH$, $-(CH_2)_m-C(=O)O-R^8$, ethyl or propyl;

each R^8 is independently H, methyl, ethyl, propyl, isopropyl, butyl, 1-methylpropyl, 2-methylpropyl, *tert*-butyl, aminomethyl, 1-amino-2-methylpropyl, 1-aminoethyl, 2-aminoethyl, 1-aminobutyl, 1-aminopropyl, 2-aminopropyl, Boc-NH-methyl, 1-Boc-NH-2-methylpropyl, 1-Boc-NH-ethyl, 2-Boc-NH-ethyl, 1-Boc-NH-butyl, 1-Boc-NH-propyl, 2-Boc-NH-propyl, methoxy, ethoxy, $-(CH_2)_m-OH$, $-(CH_2)_m-C(=O)O-(CH_2)_m-H$ or $-(CH_2)_m-OC(=O)-(CH_2)_m-H$;


each R^{8a} is independently H, methyl, ethyl, isopropyl or propyl;


each R^9 is independently $-(CR^7R^{7a})_t-OH$, $-(CR^7R^{7a})_m-C(=O)O-R^8$, $-(CR^7R^{7a})_m-C(=O)O-(CR^7R^{7a})_m-OC(=O)O-R^8$, $-(CR^7R^{7a})_m-C(=O)O-(CR^7R^{7a})_m-OC(=O)-R^8$, $-(CR^7R^{7a})_t-OC(=O)-R^8$, or $-(CR^7R^{7a})_m-C(=O)N(R^8)_2$, with the proviso that when R^9 is $-(CR^7R^{7a})_t-OH$, R^3 is phenyl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl;

each m is independently 0, 1, 2, 3 or 4; and


each t is independently 1, 2, 3 or 4.

11. The compound according to claim 10, wherein Z is:







12. The compound according to claim 9, wherein each R^3 is independently:




13. The compound according to claim 1 having one of the following structures:




1




2




3




4 ,




5 ,




6 ,




7 ,




8 ,




9 ,




10 ,




11 ,




12 ,




13 ,




14 ,




15 ,




16 ,




17 ,




18 ,




19 ,




20 ,




21 ,




22 ,




23 ,




24 ,




25 ,




26 ,




27 ,




28 ,




29 ,




30 ,




31 ,




32 ,




33 ,




34 ,




36 ,




37 ,




38 ,




39 ,




40 ,




41 ,




42 ,




43 ,




44




45




46




47




48




49




50




51




52




53




54




55




56 ,




57 ,




58 ,




59 ,




60 ,




61 ,




62 ,




63 ,




64 ,




65 ,




66 ,




67 ,




68




69




70




71




72




73




74




75




76




77




78




79




80




81




82




83




84




85




86




87




88




89




90




91 ,




92 ,




93 ,




94 ,




95 ,




96 ,




97 ,




98 ,




99 ,




100 ,




101




102




103




104




105




106




107




108




109




110




111 ,




112 ,




113 ,




114 ,




115 ,




116 ,




117 ,




118 ,




119,




120,




121,




122,




123,




124,




125,




126,




127,





128,





129,



130



131



132



133



134



135



136



137


138



139


140



141




142 ,




143 ,




144 ,




145 ,




146 ,




147 ,




148 ,




149 ,




150 ,




151 ,




152 ,




153 ,




154 ,




156 ,




157 ,




158 ,




159 ,




160 ,




161 ,




162 ,




163 ,




164 ,




165 ,




166 ,




167 ,




168 ,




169 ,




170 ,



171 ,




172 and



173 ,

or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 9 having Formula (IV):




(IV),


wherein n of formula (IV) is 2;

each R^{13} is independently F or Br;

R^2 is C_{1-4} alkyl; and

R^3 is  ; and

wherein Z has Formula (II):



(II),

n of formula (II) is 1;

R^9 is $-(CR^7R^{7a})_m-C(=O)O-R^8$, where m is 0 and R^8 is H;

B is a bond;

W is N; and

Y is $-(CR^7R^{7a})_m-$, where and each R^{7a} and R^7 is independently F.

15. A pharmaceutical composition comprising the compound according to any one of claims 1-14; and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof.

16. The pharmaceutical composition according to claim 15 further comprises an anti-HBV agent.

17. The pharmaceutical composition according to claim 16, wherein the anti-HBV agent is a HBV polymerase inhibitor, immunomodulator or interferon.

18. The pharmaceutical composition according to claim 16, wherein the anti-HBV agent is lamivudine, telbivudine, tenofovir, entecavir, adefovir dipivoxil, alfaferone, alloferon, celmoleukin, clevudine, emtricitabine, famciclovir, feron, hepatect CP, intefen, interferon α-1b, interferon α, interferon α-2a, interferon β-1a, interferon α-2, interleukin-2, mivotilate, nitazoxanide, peginterferon alfa-2a, ribavirin, roferon-A, sizofiran, euforavac, veldona, rintatolimod, phosphazid, heplisav, interferon α-2b, levamisole, or propagermanium.

19. The compound according to any one of claims 1-14 or the pharmaceutical composition according to any one of claims 15-18 for use in preventing, managing, treating or lessening a HBV disease.

20. The compound or the pharmaceutical composition according to claim 19, wherein the HBV disease is hepatitis B infection or a disease caused by hepatitis B infection.

21. The compound or the pharmaceutical composition according to claim 20, wherein the disease caused by hepatitis B infection is cirrhosis or hepatocellular carcinoma.